Re: Question
Any presentations at AACR on April1-5?
How has Geron improved their telomerase inhibitor drug since the days of Thomas O'karma who was the CEO when Geron also had the HESC platform? Prior to Janssen, the telomerase inhibitor was so slow to develop and show meaningful results. I assume that Geron has made some improvements since?.
Also, the previous data was almost "too good to be true". Where can I find that data? Exactly how good was it??
Also, why doesn't Geron apply this inhibitor to other cancer types such as breast, lung, prostate, or blood cancers? Would approve for one indication allow I to be usedfoff label?
How expensive it it to manufacture? Would there be good gross profits? Can it be applied off the shelf to any patient, unlike Dendreon's patient specific prostate drug Provenge, which left little gross profit dur to high COGS.
Sorry for the many questions. I hold a decent stake but am looking to acquire more.
Many many thanks.!!!